OPO. A. Pylaeva

O. A. Pylaeva

*This is an algorithmically generated author record based on publicly available information.

O. A. Pylaeva has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lamotrigine (Sazar) in the treatment of epilepsy: seven years of experience in Svt. Luka’s Association of Medical Institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy

    by М. Yu. Bobylova, Бобылова М. Ю., Larisa Yu. Glukhova, Глухова Лариса Юрьевна, К. Yu. Мukhin, Мухин К. Ю., O. A. Pylaeva, Пылаева О. А.

    Aim. To assess the efficacy and tolerability of lamotrigine (Sazar; LLC “Alkaloid-Rus”, Republic of Macedonia) for various forms of epilepsy, based on long-term experience of Svt. Luka Association of Medical Institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy (Svt. Luka’s Institute of Child Neurology and Epilepsy/Svt. Luka’s Institute of Child and Adult Neurology and Epilepsy). Materials and methods. A retrospective cohort study was conducted based on the analysis of clinical data from 628 patients (aged 3 to 46 years; 595 children and 33 adults (20 women and 13 men); mean age 10.5 years; 319 males and 309 females) monitored at Svt. Luka Association of Medical Institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy who received Sazar over a 7-year period (from June 2018 to September 2025). Distribution by epilepsy types: structural and presumably structural focal epilepsy/focal epilepsy of unknown etiology (n = 496); genetic and presumably genetic epilepsies, as well as developmental and epileptic encephalopathies (n = 97); idiopathic generalized epilepsies (n = 35). Sazar was administered as adjunctive therapy or monotherapy at a dose of 3–5 mg/kg/day, with gradual titration over 4–8 weeks to a target dose of 37.5–500.0 mg/day. Subsequently, the dose of Seizar was adjusted depending on the clinical effect, electroencephalography findings, and blood drug concentrations. Three adult female patients received Sazar as a single daily dose of 200 mg/day (at bedtime in 2 cases, and in the morning in 1 case). In all other cases, patients received Sazar twice daily. Sazar was administered as monotherapy in 176 patients or as adjunctive treatment to other antiepileptic drugs in 452 patients (combination of Sazar with one antiepileptic drug occurred in 379 patients, and with two antiepileptic drugs in 73 patients). In five patients, valproate was added to Sazar, achieving a therapeutic effect without subsequent discontinuation of Sazar. In two patients with high treatment efficacy, a subsequent successful switch from polytherapy to Sazar monotherapy became possible. Twelve patients previously treated with another lamotrigine generic were switched to Sazar without any worsening of epilepsy course. The follow-up period ranged from 6 months to more than 7 years. Patients followed up for at least 6 months were included in the analysis. Results. Therapeutic remission was achieved in 306 out of 628 patients (48.72 %) receiving Sazar. Therapeutic remission with Sazar was achieved in 306 out of 628 patients (48.72 %). An additional 157 out of 628 patients (25 %) showed an at least 50 % reduction in seizure frequency; 165 patients had no therapeutic effect (26.3 %). In 113 cases (17.9 %), Sazar was discontinued due to insufficient efficacy or loss of the initial robust response (after 6–12 months of treatment). Overall, a therapeutic effect (remission or an at least 50 % reduction in seizure frequency) was achieved in 463 out of 628 patients (73.7 %). Given the predominance of patients with drug-resistant forms of epilepsy in this study, this rate can be considered exceptionally high. Considering that the study population predominantly consisted of patients with drug-resistant forms of epilepsy, this rate can be considered exceptionally high. Sazar demonstrated the highest efficacy in focal epilepsies (structural, presumably structural, structural-genetic, and that of unidentified etiology), as well as in idiopathic generalized epilepsy syndromes. Efficacy was lower in genetic generalized epilepsies and epileptic encephalopathies. The majority of the patients (n = 573 (91.3 %)) demonstrated good tolerability of Sazar. Sazar-associated side effects were reported in 55 patients (8.76 %). In most cases, transient disturbances such as dizziness, headache, tremor, and nausea were observed, none of which required discontinuation of the medication. Allergic reactions predominantly manifested as a skin rash, which was reported in 37 out of 628 patients (5.8 %), within the first two months of therapy. Angioedema (Quincke’s edema) was reported in one patient. Discontinuation of Sazar due to poor tolerability was required in only 15 of 628 patients (2.4 %), with allergic reactions being the sole reason for treatment cessation. In the remaining cases, the skin rash was transient, did not require drug discontinuation, and its association with lamotrigine treatment remained unproven. Two female patients of reproductive age started Sazar to reduce the valproate dose that caused severe menstrual disorders, weight gain, alopecia, and edema. Halving the dose of valproate (up to 750 mg/day) in combination with Sazar significantly improved treatment tolerance. One patient gave birth to a healthy baby when she was receiving monotherapy with Sazar at a dose of 350 mg/day. Improvements in mood (in adult patients) as well as behavior, development, and learning (in children) during Sazar therapy were observed in 380 of 628 patients (60.5 %). In five cases, improvements in mental status during Sazar therapy enabled the discontinuation of antidepressants in adult patients with previously diagnosed depression. No negative effects of Sazar on memory, attention, mood, or behavior were observed in any of the cases, as reported by patients and parents, and in some instances, by a neuropsychologist. The high efficacy and favorable tolerability of Sazar are confirmed by treatment adherence data, with 500 of 628 patients (79.6 %) continuing the drug throughout the follow-up period (range: 6 months to 7 years). These data indicate that, with correct titration and close clinical monitoring, lamotrigine can be considered a well-tolerated drug. This is particularly significant for children with comorbid developmental and behavioral disorders, for whom sedative effects and cognitive slowing...

  • Open Access

    Forced normalization syndrome (Landolt phenomenon) as an unusual side effect of antiepileptic therapy. Literature review and clinical cases

    by O. A. Pylaeva, K. Yu. Mukhin, A. N. Ulyakov, A. A. Markin, Мухин К. Ю.

    In general, mental disorders are 2–3 times more common in epilepsy than in the general population without epilepsy and can be caused by a combination of factors, including the side effects of antiepileptic drugs. However, only in rare cases is the development of mental disorders in epilepsy associated with significant improvement in the course of epilepsy and the onset of seizure remission due to the high efficacy of antiepileptic therapy or epilepsy surgery. This article discusses forced normalization syndrome (Landolt phenomenon), which can be considered an unusual side effect of antiepileptic therapy. It provides a definition, history of study, proposed pathogenesis, clinical and electroencephalographic presentation, diagnostic criteria for Landolt syndrome, and patient management strategies for this condition. A detailed review of the current literature and descriptions of clinical cases of patients observed by us are presented. More than 1,000 years after its first description, this phenomenon remains a mystery to clinicians. Informing physicians about the possibility of Landolt syndrome is of practical importance, as the syndrome is likely more common than recognized and is often underdiagnosed. However, awareness of the possibility of this complication of drug therapy for epilepsy allows for timely discontinuation of the offending medication, which interrupts the progression of mental disorders and promotes mental stabilization.

  • Open Access

    Definition and new approaches to understanding the pathogenesis of Drave syndrome in children

    by A. N. Ulyakov, M. Yu. Bobylova, V. S. Lobanova, К. Yu. Мukhin, O. A. Pylaeva, I. S. Tishchenko, S. O. Kazakov, К. Ю. Мухин

    Nowadays, Dravet syndrome is one of the most studied forms of genetic epilepsy. Despite a large number of studies and publications, Dravet syndrome remains a difficult neurological disease to treat. The relationship of epileptogenesis in Dravet syndrome with the activity of sodium channels has been studied, and data on the different effectiveness and ineffectiveness of anticonvulsant drugs with different mechanisms of action have been obtained. Drugs that modify neural transmission, enhance inhibitory transmission, and reduce excitatory transmission, as well as their combination, are more effective. Drugs that reduce the effect of inhibitory transmission (in particular, sodium channel blockers) should not be used. In our opinion, the correct choice of therapy for Dravet syndrome associated with a mutation in the SCN1A gene is possible only from the perspective of understanding the work of neural channels in the brain.


  • Open Access

    New possibilities of using perampanel in children. Efficacy and tolerability of perampanel in the treatment of epilepsy (literature review and experience of Svt. Luka’s Association of Medical Institutions)

    by K. Yu. Mukhin, O. A. Pylaeva, M. Yu. Bobylova, L. Yu. Glukhova, К. Ю. Мухин, Л. Ю. Глухова

    Aim. To assess the efficacy and tolerability of perampanel as an additional therapy in epilepsy patients treated in St. Luke Association of medical institutions (including Svt. Luka’s Institute of Child Neurology and Epilepsy / Svt. Luka’s Institute of Pediatric and Adult Neurology and Epilepsy) with a focus on the order of perampanel administration (in groups of early and late additional therapy with perampanel).Materials and methods. This study included 270 patients aged 4 to 43 years (125 males and 145 females; 255 children and adolescents aged 4–18 years; 15 adult patients; mean age at the time of perampanel therapy initiation was 11.8 years) who received perampanel and for whom we managed to collect clinical data for at least 6 months.The study sample included 114 patients with structural and presumably structural focal epilepsy, 120 patients with genetic and presumably genetic epilepsy (including Dravet and Angelman syndromes, Lafora disease, mutations in genes PCDH19, PHACTR1, CDKL5, ARX, PING, SCN2A, KIAA2022, chromosomal microdeletions, etc.), and 36 patients with focal epilepsy of unknown etiology. In all patients, perampanel was used as an additional antiepileptic drug (AED), primarily in combination with valproate. The next most common AEDs were carbamazepine, oxcarbazepine, vigabatrin, ethosuximide (mainly in combination with valproate), levetiracetam, and topiramate; other AEDs were used significantly less often. Drug titration was performed in accordance with recommendations (dosage increase by 2 mg each 1–2 weeks) up to the therapeutic dose of 4–12 mg / day taken before sleep. The majority of patients received perampanel at a dose of 6 mg.Total duration of perampanel therapy varied between 4 and 11 months. Patients were divided into three groups: patients in group 1 received perampanel as a second drug in additional therapy (n = 21); patients in group 2 received perampanel as a third drug in additional therapy (n = 54); patients in group 3 received perampanel as at least forth drug in additional therapy (n = 195). Groups 1 and 2 were considered as groups of early additional perampanel therapy, whereas group 3 was considered as a group of late additional perampanel therapy.To evaluate perampanel efficacy, we measured proportions of responders (who demonstrated at least 50 % reduction seizure frequency compared to baseline, including patients in remission) and patients who achieved remission (no seizures over the last 6 months). Patients with a less than 50 % reduction in seizure frequency were considered as those with no significant effect. Patients who had no therapeutic effect or had aggravation (more frequent or severe seizures) in response to perampanel initiation or change of other AED to perampanel were considered as those with no effect or aggravation. We also assessed 6-month and 12-month retention rates. The main tolerability criteria were the number of side effects and proportion of patients who discontinued perampanel due to pronounced side effects.Results. The overall proportion of responders was 76 % (206 out of 270); 21.4 % of patients achieved remission (58 out of 270). No significant effect was observed in 19.6 % of patients (53 out of 270), while 4 % of patients (11 out of 270) had no effect or even aggravation. In group 1 (early therapy with perampanel as a second additional drug; n = 21), 8 out of 21 patients (38 %) achieved an at least 6-month remission; the proportion of responders reached 95.2 % (20 out of 21), while 1 patient had no significant effect. In group 2 (early therapy with perampanel as a third additional drug; n = 54), there were 83 % of responders (45 out of 54) and 25.9 % patients with remission (14 out of 54); 16.7 % of patients demonstrated no significant effect (9 out of 54); none of the patients had aggravation. Cumulative analysis of the data in groups 1 and 2 (early additional therapy with perampanel; n = 75) showed that the proportion of responders reached 86.7 % (65 out of 75), while the proportion of patients with remission was 29.3 % (22 out of 75). Ten out of 75 patients from groups 1 and 2 (13.3 %) had no significant effect; none of the patients had aggravation. In group 3 (late additional therapy with perampanel; n = 195), the proportion of responders and patients with remission was 72.3 % (141 out of 195) and 18.4 % (36 out of 195), respectively. Forty-three patients in group 3 (22 %) demonstrated no significant effect; 11 patients had no effect or aggravation (5.6 %).Thus, we observed significant differences in treatment efficacy between the groups of early and late additional perampanel therapy: 29.3 % vs 18.4 % of patients with remission and 86.7 % vs 72.3 % of responders in early and late therapy groups, respectively.Although perampanel was initiated late in the majority of patients (as forth or subsequent AED used) due to the existing recommendations and, therefore, groups of early and late additional therapy differed significantly in the number of patients, our findings predict a significant increase in perampanel efficacy if it is initiated as an early additional therapy.Of note, despite the fact that the majority of patients started to receive perampanel late, the overall perampanel efficacy was relatively high as demonstrated by 76 % of responders and 21.4 % of patients with remission.Perampanel was characterized by good tolerability, which did not differ between the groups. A total of 129 out of 270 patients (47.8 %) reported side effects, most of them were mild or moderate. Importantly, 80 cases of side effects were considered desirable, including improved sleep (sedative effect of perampanel in combination with taking the drug before bedtime) and decreased muscle tone (45 % of parents of children with cerebral palsy reported decreased spastic hypertension in their children). The most common side effects included drowsiness, lethargy, decreased muscle tone, dizziness, and...


  • Open Access

    Efficacy and tolerability of sulthiame in the treatment of epilepsy: a literature review

    by K. Yu. Mukhin, O. A. Pylaeva, А. V. Мarkin, К. Ю. Мухин

    This review aims to summarize the available evidence on the efficacy and tolerability of sulthiame for different forms of epilepsy. The analysis of international publications suggests that sulthiame is considered as a first-line drug for the treatment of age-dependent epilepsy with central temporal spikes (rolandic epilepsy). Sulthiame is highly effective in children with epileptic encephalopathies manifesting with spike-and-wave activity during sleep, including Landau-Kleffner syndrome, as well as in patients with myoclonic seizures. The drug might be also effective in patients with other forms of focal epilepsy, including those resistant to therapy. The tolerability of sulthiame is higher that that of old antiepileptic drugs and even levetiracetam; thus, it is associated with a lower risk of treatment interruptions due to adverse events. Moreover, sulthiame can be used for behavioral disorders (such as hyperkinetic behavior, aggressiveness) and cognitive impairments. Sulthiame can be effective in patients with epilepsy and sleep apnea.


  • Open Access

    The modern approaches to the diagnostics and treatment of Lennox–Gastaut syndrome (literature review)

    by K. Yu. Mukhin, O. A. Pylaeva, К. Ю. Мухин

    Despite significant advances made in epileptology, treatment-resistant epilepsy accounts for approximately 30 % of all forms of this disease. Such diseases include, among others, Lennox–Gastaut syndrome – a classic developmental and epileptic encephalopathy with onset in childhood, characterized by resistance to therapy, severe course and poor prognosis. For patients in this category, the search for new effective antiepileptic drugs remains highly relevant, especially in cases where numerous combinations of antiepileptic drugs do not produce an effect, surgical treatment is impossible, and alternative methods (vagus nerve stimulation and ketogenic diet) are ineffective. The authors present a review of the literature on the modern definition and diagnostic criteria of Lennox–Gastaut syndrome, diagnostic methods and treatment of this form of epilepsy, which has a severe course and a generally unfavorable prognosis.


  • Open Access

    Efficacy and tolerability of rufinamide in the treatment of Lennox–Gastaut syndrome (experience of the Svt. Luka’s Association of Medical Institutions)

    by K. Yu. Mukhin, O. A. Pylaeva, M. Yu. Bobylova, L. Yu. Glukhova, N. V. Freydkova, К. Ю. Мухин, Л. Ю. Глухова

    Background. Lennox–Gastaut syndrome (LGS) is a classic developmental and epileptic encephalopathy with a debut in childhood, characterized by resistance to therapy, a severe course, and an unfavorable prognosis. Due to the existing difficulties in treatment of LGS, hopes are pinned on development of new antiepileptic drugs with fundamentally different mechanisms of action, aimed specifically at the treatment of this severe form of epilepsy.Rufinamide (Inovelon®) is a new antiepileptic drug registered in the Russian Federation for use in the adjunctive therapy of LGS in patients older than 1 year. The main mechanism of action of rufinamide is the restriction of neuronal discharges associated with the blocking effect on sodium channels (regulation of sodium channels activity by increasing duration of their inactive state), and stabilization of neuronal membranes. The drug has a number of advantages concernung pharmacokinetic parameters and efficacy (including a wide spectrum of antiepileptic activity, good oral absorption, absence of active metabolites, urinary excretion, low affinity for plasma proteins, biotransformation without cytochrome P450 isoenzymes, low risk of drug interactions) and fairly good tolerability. The daily dose of rufinamide varies from 600 mg (with simultaneous administration of valproate) to 1000 mg (if the patient does not take valproate) in children over 4 years of age with a body weight of less than 30 kg and up to 2200–3200 mg in children over 4 years of age with a body weight of more than 30 kg and in adults; in children under 4 years of age, the maximum daily dose in combination with valproate is 30 mg/kg, and without valproic acid – 45 mg/kg.Aim. To analyze the efficacy and tolerability of rufinamide in the treatment of epilepsy based on the long-term experience of using the drug in the Svt. Luka’s Association of Medical Institutions.Materials and methods. We observed 64 patients aged from 1.5 to 26 years (44 men, 20 women) treated with rufinamide (Inovelon®). Among them, the structural etiology LGS was diagnosed in 36 patients, the genetic and presumably genetic etiology LGS – in 28. In all cases, rufinamide was used in accordance with approved indications as an additional antiepileptic drug, more often in combination with valproate, topiramate, levetiracetam or lamotrigine. Titration of the drug was carried out according to the recommendations in the instructions for use, up to a therapeutic dose that ranged from 200 to 1600 mg/day (in most cases from 400 to 1200 mg/day), depending on age and concomitant therapy.Results and conclusion. Remission of all types of seizures was registered in 17 (26.6 %) patients, and a decrease in the incidence of seizures by more than 50 % was recorded in 28 (43.8 %) patients. Of them, 13 patients demonstrated reduction in seizures frequency by more than 75–90 % and remission of one of several types of seizures. In general, the therapeutic effect (reduction of seizures frequency by at least 50 %) was achieved in 45 (70.3 %) of 64 patients. A decrease in seizures frequency of by at least 50 % was observed in 8 (12.5 %) patients; in 10 (15.6 %) patients, rufinamide therapy was not effective; in 1 (1.56 %) case an aggravation of bilateral convulsive seizures was noted when rufinamide was administered.In most cases, rufinamide is well tolerated. Our patients had side effects in 10 (15.6 %) cases. Only in 2 (3.1 %) cases, rufinamide was withdrawn directly due to side effects (the reason for withdrawal in these cases was an allergic reaction and psychosis).The retention rate for therapy lasting 1 year or more is 65.6 % (42 of 64 patients).Thus, our data have demonstrated efficacy and good tolerability of rufinamide in treating epileptic seizures associated with LGS, confirming numerous literature data. However, in our analysis, a higher rate of seizure remission was obtained, although we have included patients with mainly resistant forms of epilepsy in the analysis.


  • Open Access

    Lamotrigine (Sazar) in the treatment of epilepsy: four years of experience in Svt. Luka's Association of Medical institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy

    by K. Yu. Mukhin, O. A. Pylaeva, M. Yu. Bobylova, N. V. Freydkova, К. Ю. Мухин

    Aim. To assess the efficacy and tolerability of lamotrigine (Sazar) for various forms of epilepsy, based on long-term experience of Svt. Luka's Association of Medical Institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy. We analyzed the data obtained during 4 years (from June 2018 to August 2022).Materials and methods. We evaluated the efficacy and tolerability of Sazar in 104 patients aged 3 to 37 years (87 children and 17 adults (12 women and 5 men)); their mean age was 9.7 years. The sample included 42 males and 62 females. All of them were treated at Svt. Luka's Association of Medical Institutions for the Diagnosis, Treatment, and Rehabilitation of Nervous System Diseases and Epilepsy.The sample included patients with structural and presumably structural focal epilepsy (n = 44), focal epilepsy of unknown etiology (n = 6), genetic and presumably genetic epilepsy and epileptic encephalopathies (n = 43), idiopathic epilepsy (n = 11).Sazar was used as a monotherapy in 38 patients, whereas 66 patients received it in combination with other antiepileptic drugs (AED) (Sazar + 1 AED in 48 patients; Sazar + 2 AED in 18 patients). Two patients initially receiving polytherapy were successfully transferred to Sazar monotherapy.The dose of Sazar varied between 75 and 400 mg/day. In the majority of patients, including all children, Sazar daily dose was split into 2 portions. Three adult patients received Cazar once a day either in the evening (n = 2) or in the morning (n = 1) at a dose of 200 mg/day. The follow-up time was between 6 months and over 4 years.Results and conclusion. Therapeutic remission was achieved in 47 out of 104 patients (45.2 %) receiving Sazar. As many as 35 patients (33.6 %) demonstrated an at least 50 % reduction in seizure frequency; 22 patients had no effect (21.2 %). None of the participants developed significant aggravation.Only 9 patients (8.6 %) discontinued Caser due to its initial low efficacy, while another 8 patients (7.6 %) stopped to receive Casar because it became ineffective after 6–12 months of treatment. In general, good therapeutic effect (remission or at least 50 % reduction in seizure frequency) was achieved in 82 out of 104 patients (78.8 %). Given the fact that this study included patients with severe epilepsy, we can conclude that treatment was very effective.Casar was most effective in patients with focal epilepsy (including structural, presumably structural, structural-genetic, and that of unidentified etiology) and idiopathic generalized epilepsy.The majority of the patients (n = 94; 90.4 %) demonstrated good tolerability of Casar. Casar-associated side effects were registered in 10 patients (9.6 %). Allergic skin rash was observed in 5 cases (4.8 %) and developed during the first 2 months of therapy. Allergic reactions accounted for 50 % of all side effects and were the only reason for Casar discontinuation due to poor tolerability.Two female patients of reproductive age started Sazar to reduce the valproate dose that caused severe menstrual disorders, weight gain, alopecia, and edema. Halving the dose of valproate (up to 750 mg/day) in combination with Casar significantly improved treatment tolerance. One patient gave birth to a healthy baby when she was receiving monotherapy with Sazar at a dose of 350 mg/day.Eight patients receiving Sazar reported a significant improvement in their mood and behavior (one patient that had earlier been diagnosed with depression discontinued antidepressants after Sazar initiation since she did not need them any longer). None of the patients reported any negative effects of Sazar on their memory, attention, mood, and behavior (as evaluated by patients and parents; in some cases, by a neuropsychologist).Patients’ adherence to treatment confirmed high Sazar efficacy and tolerability: 82 out of 104 patients (78.8 %) continued to receive the drug after 6 months of treatment and 69 patients (66.3 %) still continued it after 12 months of treatment. The follow-up period varied between 6 months and 4 years.Thus, our findings suggest high efficacy and good tolerability of long-term therapy with Sazar in patients with different forms of epilepsy.


  • Open Access

    Classification and definition of epilepsy. Position paper by the International League Against Epilepsy on Nosology and Definitions of Epilepsy Syndromes dated 2021

    by K. Yu. Mukhin, O. A. Pylaeva, V. S. Kakaulina, M. Yu. Bobylova, К. Ю. Мухин

    This article presents updated and revised diagnostic criteria for epilepsy syndromes proposed in 2021 by the Nosology and Definitions Taskforce of the International League Against Epilepsy (ILAE). The current classification of epilepsy syndromes was developed in 1989. The new ILAE Classification and Definition of Epilepsy Syndromes is a result of huge work of many experts from all over the world. The draft of the new classification is presented on the ILAE website for wide discussion. It includes 4 main sections: 1) classification and definition of epilepsy syndrome with onset in neonates and infants; 2) classification and definition of epilepsy syndromes with onset in childhood; 3) classification and definition of epilepsy syndromes with onset at a variable age; 4) definition of the idiopathic generalized epilepsy syndromes. Each section is based on a thorough analysis of literature and clinical experience of experts. Its main purpose is to identify epilepsy syndromes using the 2017 ILAE classification of epilepsy forms and types of epileptic seizures, as well as to identify specific characteristics of each syndrome to improve clinical diagnosis. For each syndrome, the document provides the details on its epidemiology, clinical manifestations, types of seizures, electroencephalographic features, neuroimaging signs, genetic examination, as well as differential diagnosis with other epilepsy syndromes and various non-epileptic conditions. It introduces mandatory criteria that must be present in order to diagnose the syndrome and alert criteria that are absent in the vast majority of cases within a syndrome, but rarely can be seen. Particular attention is paid to exclusionary criteria that must be absent in order to diagnose the syndrome. When developing the criteria for each epilepsy syndrome, the ILAE Task Force used the latest literature data, including Internet resources and the opinion of experts in this area. The international classification should be applied by specialists from all over the world. It should contain clear and easy-to-understand definitions; the language should be simple and understandable. The new ILAE classification demonstrates revised definitions of well-known electroclinical epilepsy syndromes and proposes a new concept of defining epilepsy syndromes by their etiology (including those syndromes in which pathogenic mutations or structural changes correlate significantly with certain electroclinical phenotype). It also introduces a new etiology-defined class of epilepsy syndromes characterized by specific genetic, metabolic, and structural causes. The document does not cover therapy for epilepsy syndromes; however, for some of them, it specifies the most effective or potentially aggravating antiepileptic drugs. The prospect of further targeted gene therapies development and approval of antiepileptic drugs specific for certain epilepsy syndromes after randomized clinical trials had served as a powerful motivation to introduce the concept of epilepsy syndromes determined primarily by etiology. In conclusion, the authors discuss the Classification and Definition of Epilepsy Syndromes, propose their ideas, comments, suggestions, and observations. This article aims to familiarize a wide range of specialists with the new ILAE classification and its details. In addition to a detailed description of the abovementioned document, the article provides information on the currently existing classification principles for epilepsy and epileptic seizures. There is also a discussion with the authors’ comments on the ILAE Classification and Definition of Epilepsy Syndromes.


  • Epilepsy in Angelman syndrome

    by M.YU. Bobylova, K.YU. Mukhin, G.V. Kuzmich, L.YU. Glukhova, O.A. Pylayeva

    ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение неврологического статуса, клинико-ЭЭГ-картины, нейровизуализации и течения эпилепсии у детей с генетически подтвержденным синдромом Ангельмана. МАТЕРИАЛ И МЕТОДЫ Проанализированы данные 47 пациентов (26 мальчиков и 21 девочка в возрасте от 2 до 20 лет, средний возраст 8,5 года) с генетически верифицированным диагнозом «синдром Ангельмана». Диагноз установлен методом метилирования ДНК у 32 пациентов и секвенирования у 15 (при этом выявлено 12 случаев делеции и 3 — нуклеотидной замены). РЕЗУЛЬТАТЫ У 45 из 47 пациентов отмечается эпилепсия. Приступы дебютировали до 5 лет включительно. Для лечения пациенты получали различные антиэпилептические препараты. Длительный катамнез по эпилепсии удалось проследить у 40 из 47 пациентов, у 36 из 40 — достигнута медикаментозная ремиссия. Через несколько лет ремиссии у 24 из 36 пациентов произошел рецидив, который удалось быстро купировать у 23 пациентов. На степень тяжести заболевания влияют характер мутации и протяженность делеции, а также персистирующие эпилептические приступы. Максимально эффективными антиэпилептическими препаратами у пациентов в исследовании оказались вальпроевая кислота, леветирацетам, этосуксимид в монотерапии; вальпроевая кислота в сочетании с леветирацетамом или этосуксимидом, реже леветирацетам с этосуксимидом в дуотерапии. ЗАКЛЮЧЕНИЕ Ранняя генетическая диагностика синдрома Ангельмана облегчает подбор противоэпилептической терапии.